Avidity Biosciences, Inc. (RNA)
NASDAQ: RNA · Real-Time Price · USD
28.96
+0.56 (1.97%)
May 15, 2025, 4:00 PM - Market closed
Avidity Biosciences Stock Forecast
Stock Price Forecast
According to 12 professional analysts, the 12-month price target for Avidity Biosciences stock ranges from a low of $53 to a high of $96. The average analyst price target of $67.92 forecasts a 134.53% increase in the stock price over the next year.
Price Target: $67.92 (+134.53%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Avidity Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Buy | 5 | 4 | 4 | 6 | 6 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 10 | 10 | 12 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $72 → $68 | Strong Buy | Maintains | $72 → $68 | +134.81% | May 12, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $65 | Strong Buy | Maintains | $65 | +124.45% | May 9, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $65 | Strong Buy | Maintains | $65 | +124.45% | May 7, 2025 |
| Needham | Needham | Strong Buy Reiterates $60 | Strong Buy | Reiterates | $60 | +107.18% | Apr 9, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $72 | Strong Buy | Reiterates | $72 | +148.62% | Mar 18, 2025 |
Financial Forecast
Revenue This Year
6.82M
from 10.90M
Decreased by -37.39%
Revenue Next Year
15.11M
from 6.82M
Increased by 121.50%
EPS This Year
-3.94
from -2.89
EPS Next Year
-4.48
from -3.94
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 22.1M | 81.6M | 770.0M | ||
| Avg | 6.8M | 15.1M | 310.0M | ||
| Low | n/a | n/a | 78.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 102.3% | 1,095.7% | 4,994.8% | ||
| Avg | -37.4% | 121.5% | 1,951.5% | ||
| Low | - | - | 418.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.50 | -2.46 | -0.39 | ||
| Avg | -3.94 | -4.48 | -2.85 | ||
| Low | -4.89 | -5.65 | -5.04 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.